US tobacco company 22nd Century Group has enjoyed its first full quarter benefitting from revenue generated by its new hemp/cannabis business arm. The company acquired GVB Biopharma in May, expanding its existing hemp/cannabis research and development activities to include a revenue-producing business.
22nd Century Group said GVB was “the largest merchant market provider of cannabinoid extracts and isolates in North America”. It added, during a presentation of its Q3 2022 results, that it was focusing on CBG as well as CBD extracts and held about 15% market share in the hemp-derived active ingredients market.